ChangE From Any Systemic psoriasiS therapY to Raptiva

PHASE4

Phase

TERMINATED

Status

Enrollment

INDUSTRY

Sponsor class

Stopped The study was terminated after the European Medicines Agency recommended to suspend the marketing authorisation of Raptiva in the European Union

Conditions

Chronic Plaque Psoriasis

Interventions

DRUG: Efalizumab - anti CD11a recombinant human monoclonal antibody (mAb)

Sponsor

Merck KGaA, Darmstadt, Germany